Chris Schelling has a diverse work experience spanning over two decades. Chris is currently a Member of the Board of Trustees at Carroll College since May 2022. Prior to this, they were the CEO & Founder of Acer Therapeutics Inc., a pharmaceutical company focused on developing therapies for rare and life-threatening diseases. Chris founded Censa Pharmaceuticals Inc. in 2015, which was later sold to PTC Therapeutics. Chris has also held executive and managerial positions at BioMarin Pharmaceutical Inc., Abgenix, Inc., and Cell Therapeutics, Inc. Chris started their career as a Sales Representative at Organon and has also worked as a Market Research Analyst at Stanford Research Institute. Chris has extensive experience in strategic marketing and has contributed significantly to the field of healthcare and pharmaceuticals. Additionally, they have served as a Board Member for Cascade Prodrug, Incorporated.
Chris Schelling obtained a Bachelor of Arts degree from Carroll College between 1994 and 1999. Chris studied Biology (Pre-med) and History during their time there.
December, 2013 - present